Stock Analysis on Net
Stock Analysis on Net

Abbott Laboratories (NYSE:ABT) 

Adjusted Financial Ratios

Microsoft Excel

Adjusted Financial Ratios (Summary)

Abbott Laboratories, adjusted financial ratios

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Activity Ratio
Total Asset Turnover
Reported 0.52 0.55 0.59 0.57 0.48
Adjusted 0.57 0.55 0.59 0.58 0.48
Liquidity Ratio
Current Ratio
Reported 1.67 1.64 1.63 1.85 1.72
Adjusted 1.69 1.66 1.65 1.87 1.74
Solvency Ratios
Debt to Equity
Reported 0.30 0.38 0.46 0.50 0.57
Adjusted 0.38 0.41 0.48 0.53 0.59
Debt to Capital
Reported 0.23 0.28 0.31 0.34 0.36
Adjusted 0.28 0.29 0.32 0.34 0.37
Financial Leverage
Reported 1.71 1.90 2.03 2.10 2.21
Adjusted 1.82 1.87 1.97 2.03 2.13
Profitability Ratios
Net Profit Margin
Reported 31.95% 14.27% 15.88% 16.42% 12.99%
Adjusted 12.71% 13.14% 15.39% 16.65% 11.36%
Return on Equity (ROE)
Reported 28.12% 14.83% 18.90% 19.75% 13.71%
Adjusted 13.31% 13.61% 17.98% 19.59% 11.70%
Return on Assets (ROA)
Reported 16.46% 7.82% 9.31% 9.40% 6.20%
Adjusted 7.30% 7.27% 9.12% 9.65% 5.49%

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Financial ratio Description The company
Adjusted total asset turnover An activity ratio calculated as total revenue divided by adjusted total assets. Abbott Laboratories adjusted total asset turnover ratio deteriorated from 2022 to 2023 but then improved from 2023 to 2024 not reaching 2022 level.
Adjusted current ratio A liquidity ratio calculated as adjusted current assets divided by adjusted current liabilities. Abbott Laboratories adjusted current ratio improved from 2022 to 2023 and from 2023 to 2024.
Adjusted debt-to-equity ratio A solvency ratio calculated as adjusted total debt divided by adjusted total equity. Abbott Laboratories adjusted debt-to-equity ratio improved from 2022 to 2023 and from 2023 to 2024.
Adjusted debt-to-capital ratio A solvency ratio calculated as adjusted total debt divided by adjusted total debt plus adjusted total equity. Abbott Laboratories adjusted debt-to-capital ratio improved from 2022 to 2023 and from 2023 to 2024.
Adjusted financial leverage A measure of financial leverage calculated as adjusted total assets divided by adjusted total equity.
Financial leverage is the extent to which a company can effect, through the use of debt, a proportional change in the return on common equity that is greater than a given proportional change in operating income.		 Abbott Laboratories adjusted financial leverage ratio decreased from 2022 to 2023 and from 2023 to 2024.
Adjusted net profit margin An indicator of profitability, calculated as adjusted net income divided by total revenue. Abbott Laboratories adjusted net profit margin ratio deteriorated from 2022 to 2023 and from 2023 to 2024.
Adjusted ROE A profitability ratio calculated as adjusted net income divided by adjusted total equity. Abbott Laboratories adjusted ROE deteriorated from 2022 to 2023 and from 2023 to 2024.
Adjusted ROA A profitability ratio calculated as adjusted net income divided by adjusted total assets. Abbott Laboratories adjusted ROA deteriorated from 2022 to 2023 but then slightly improved from 2023 to 2024.

Abbott Laboratories, Financial Ratios: Reported vs. Adjusted

Adjusted Total Asset Turnover

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Reported
Selected Financial Data (US$ in millions)
Net sales 41,950 40,109 43,653 43,075 34,608
Total assets 81,414 73,214 74,438 75,196 72,548
Activity Ratio
Total asset turnover1 0.52 0.55 0.59 0.57 0.48
Adjusted
Selected Financial Data (US$ in millions)
Net sales 41,950 40,109 43,653 43,075 34,608
Adjusted total assets2 73,038 72,473 73,656 74,303 71,673
Activity Ratio
Adjusted total asset turnover3 0.57 0.55 0.59 0.58 0.48

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Total asset turnover = Net sales ÷ Total assets
= 41,950 ÷ 81,414 = 0.52

2 Adjusted total assets. See details »

3 2024 Calculation
Adjusted total asset turnover = Net sales ÷ Adjusted total assets
= 41,950 ÷ 73,038 = 0.57

Activity ratio Description The company
Adjusted total asset turnover An activity ratio calculated as total revenue divided by adjusted total assets. Abbott Laboratories adjusted total asset turnover ratio deteriorated from 2022 to 2023 but then improved from 2023 to 2024 not reaching 2022 level.

Adjusted Current Ratio

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Reported
Selected Financial Data (US$ in millions)
Current assets 23,656 22,670 25,224 24,239 20,441
Current liabilities 14,157 13,841 15,489 13,105 11,907
Liquidity Ratio
Current ratio1 1.67 1.64 1.63 1.85 1.72
Adjusted
Selected Financial Data (US$ in millions)
Adjusted current assets2 23,903 22,911 25,486 24,552 20,729
Current liabilities 14,157 13,841 15,489 13,105 11,907
Liquidity Ratio
Adjusted current ratio3 1.69 1.66 1.65 1.87 1.74

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Current ratio = Current assets ÷ Current liabilities
= 23,656 ÷ 14,157 = 1.67

2 Adjusted current assets. See details »

3 2024 Calculation
Adjusted current ratio = Adjusted current assets ÷ Current liabilities
= 23,903 ÷ 14,157 = 1.69

Liquidity ratio Description The company
Adjusted current ratio A liquidity ratio calculated as adjusted current assets divided by adjusted current liabilities. Abbott Laboratories adjusted current ratio improved from 2022 to 2023 and from 2023 to 2024.

Adjusted Debt to Equity

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Reported
Selected Financial Data (US$ in millions)
Total debt 14,125 14,679 16,773 18,050 18,747
Total Abbott shareholders’ investment 47,664 38,603 36,686 35,802 32,784
Solvency Ratio
Debt to equity1 0.30 0.38 0.46 0.50 0.57
Adjusted
Selected Financial Data (US$ in millions)
Adjusted total debt2 15,275 15,873 17,946 19,251 19,890
Adjusted total shareholders’ investment3 40,046 38,712 37,370 36,607 33,604
Solvency Ratio
Adjusted debt to equity4 0.38 0.41 0.48 0.53 0.59

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Debt to equity = Total debt ÷ Total Abbott shareholders’ investment
= 14,125 ÷ 47,664 = 0.30

2 Adjusted total debt. See details »

3 Adjusted total shareholders’ investment. See details »

4 2024 Calculation
Adjusted debt to equity = Adjusted total debt ÷ Adjusted total shareholders’ investment
= 15,275 ÷ 40,046 = 0.38

Solvency ratio Description The company
Adjusted debt-to-equity ratio A solvency ratio calculated as adjusted total debt divided by adjusted total equity. Abbott Laboratories adjusted debt-to-equity ratio improved from 2022 to 2023 and from 2023 to 2024.

Adjusted Debt to Capital

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Reported
Selected Financial Data (US$ in millions)
Total debt 14,125 14,679 16,773 18,050 18,747
Total capital 61,789 53,282 53,459 53,852 51,531
Solvency Ratio
Debt to capital1 0.23 0.28 0.31 0.34 0.36
Adjusted
Selected Financial Data (US$ in millions)
Adjusted total debt2 15,275 15,873 17,946 19,251 19,890
Adjusted total capital3 55,321 54,585 55,316 55,858 53,494
Solvency Ratio
Adjusted debt to capital4 0.28 0.29 0.32 0.34 0.37

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Debt to capital = Total debt ÷ Total capital
= 14,125 ÷ 61,789 = 0.23

2 Adjusted total debt. See details »

3 Adjusted total capital. See details »

4 2024 Calculation
Adjusted debt to capital = Adjusted total debt ÷ Adjusted total capital
= 15,275 ÷ 55,321 = 0.28

Solvency ratio Description The company
Adjusted debt-to-capital ratio A solvency ratio calculated as adjusted total debt divided by adjusted total debt plus adjusted total equity. Abbott Laboratories adjusted debt-to-capital ratio improved from 2022 to 2023 and from 2023 to 2024.

Adjusted Financial Leverage

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Reported
Selected Financial Data (US$ in millions)
Total assets 81,414 73,214 74,438 75,196 72,548
Total Abbott shareholders’ investment 47,664 38,603 36,686 35,802 32,784
Solvency Ratio
Financial leverage1 1.71 1.90 2.03 2.10 2.21
Adjusted
Selected Financial Data (US$ in millions)
Adjusted total assets2 73,038 72,473 73,656 74,303 71,673
Adjusted total shareholders’ investment3 40,046 38,712 37,370 36,607 33,604
Solvency Ratio
Adjusted financial leverage4 1.82 1.87 1.97 2.03 2.13

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Financial leverage = Total assets ÷ Total Abbott shareholders’ investment
= 81,414 ÷ 47,664 = 1.71

2 Adjusted total assets. See details »

3 Adjusted total shareholders’ investment. See details »

4 2024 Calculation
Adjusted financial leverage = Adjusted total assets ÷ Adjusted total shareholders’ investment
= 73,038 ÷ 40,046 = 1.82

Solvency ratio Description The company
Adjusted financial leverage A measure of financial leverage calculated as adjusted total assets divided by adjusted total equity.
Financial leverage is the extent to which a company can effect, through the use of debt, a proportional change in the return on common equity that is greater than a given proportional change in operating income.		 Abbott Laboratories adjusted financial leverage ratio decreased from 2022 to 2023 and from 2023 to 2024.

Adjusted Net Profit Margin

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Reported
Selected Financial Data (US$ in millions)
Net earnings 13,402 5,723 6,933 7,071 4,495
Net sales 41,950 40,109 43,653 43,075 34,608
Profitability Ratio
Net profit margin1 31.95% 14.27% 15.88% 16.42% 12.99%
Adjusted
Selected Financial Data (US$ in millions)
Adjusted net earnings2 5,331 5,270 6,718 7,173 3,933
Net sales 41,950 40,109 43,653 43,075 34,608
Profitability Ratio
Adjusted net profit margin3 12.71% 13.14% 15.39% 16.65% 11.36%

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Net profit margin = 100 × Net earnings ÷ Net sales
= 100 × 13,402 ÷ 41,950 = 31.95%

2 Adjusted net earnings. See details »

3 2024 Calculation
Adjusted net profit margin = 100 × Adjusted net earnings ÷ Net sales
= 100 × 5,331 ÷ 41,950 = 12.71%

Profitability ratio Description The company
Adjusted net profit margin An indicator of profitability, calculated as adjusted net income divided by total revenue. Abbott Laboratories adjusted net profit margin ratio deteriorated from 2022 to 2023 and from 2023 to 2024.

Adjusted Return on Equity (ROE)

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Reported
Selected Financial Data (US$ in millions)
Net earnings 13,402 5,723 6,933 7,071 4,495
Total Abbott shareholders’ investment 47,664 38,603 36,686 35,802 32,784
Profitability Ratio
ROE1 28.12% 14.83% 18.90% 19.75% 13.71%
Adjusted
Selected Financial Data (US$ in millions)
Adjusted net earnings2 5,331 5,270 6,718 7,173 3,933
Adjusted total shareholders’ investment3 40,046 38,712 37,370 36,607 33,604
Profitability Ratio
Adjusted ROE4 13.31% 13.61% 17.98% 19.59% 11.70%

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
ROE = 100 × Net earnings ÷ Total Abbott shareholders’ investment
= 100 × 13,402 ÷ 47,664 = 28.12%

2 Adjusted net earnings. See details »

3 Adjusted total shareholders’ investment. See details »

4 2024 Calculation
Adjusted ROE = 100 × Adjusted net earnings ÷ Adjusted total shareholders’ investment
= 100 × 5,331 ÷ 40,046 = 13.31%

Profitability ratio Description The company
Adjusted ROE A profitability ratio calculated as adjusted net income divided by adjusted total equity. Abbott Laboratories adjusted ROE deteriorated from 2022 to 2023 and from 2023 to 2024.

Adjusted Return on Assets (ROA)

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Reported
Selected Financial Data (US$ in millions)
Net earnings 13,402 5,723 6,933 7,071 4,495
Total assets 81,414 73,214 74,438 75,196 72,548
Profitability Ratio
ROA1 16.46% 7.82% 9.31% 9.40% 6.20%
Adjusted
Selected Financial Data (US$ in millions)
Adjusted net earnings2 5,331 5,270 6,718 7,173 3,933
Adjusted total assets3 73,038 72,473 73,656 74,303 71,673
Profitability Ratio
Adjusted ROA4 7.30% 7.27% 9.12% 9.65% 5.49%

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
ROA = 100 × Net earnings ÷ Total assets
= 100 × 13,402 ÷ 81,414 = 16.46%

2 Adjusted net earnings. See details »

3 Adjusted total assets. See details »

4 2024 Calculation
Adjusted ROA = 100 × Adjusted net earnings ÷ Adjusted total assets
= 100 × 5,331 ÷ 73,038 = 7.30%

Profitability ratio Description The company
Adjusted ROA A profitability ratio calculated as adjusted net income divided by adjusted total assets. Abbott Laboratories adjusted ROA deteriorated from 2022 to 2023 but then slightly improved from 2023 to 2024.